MARKET

EXEL

EXEL

Exelixis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

25.24
-0.32
-1.25%
After Hours: 25.18 -0.06 -0.24% 17:55 05/17 EDT
OPEN
25.54
PREV CLOSE
25.56
HIGH
25.74
LOW
25.09
VOLUME
850.10K
TURNOVER
--
52 WEEK HIGH
27.35
52 WEEK LOW
18.18
MARKET CAP
7.91B
P/E (TTM)
126.07
1D
5D
1M
3M
1Y
5Y
Bristol Myers (BMY) Announces New Data on Cardiovascular Candidate
Zacks.com · 6h ago
Stephens Investment Management Group LLC Buys Revolve Group Inc, Ameresco Inc, Onto Innovation ...
GuruFocus News · 3d ago
CM Management, LLC Buys Amicus Therapeutics Inc, Alico Inc, Exelixis Inc, Sells Aterian Inc, ...
GuruFocus News · 5d ago
Ipsen partners with Exelixis to develop Cabometyx for thyroid cancer
Ipsen (IPSEY) has exercised its option to collaborate with Exelixis (EXEL) in a pivotal trial for Cabometyx (cabozantinib) in patients with radioiodine-refractory differentiated thyroid cancer ((DTC)).Following the exercise of the option, Ipsen
Seekingalpha · 5d ago
8-K: EXELIXIS, INC.
(EDGAR Online via COMTEX) -- 5/7/202100009397672021FYfalse00009397672019-07-312019-07-3100009397672021-05-072021-05-07 UNITED STATES SECURITIES AND EXCHANGE...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 5d ago
BRIEF-Exelixis Says Notified By Ipsen Pharma That Ipsen Exercised Its Option To Collaborate With Co In Phase 3 Cosmic-311 Pivotal Trial
reuters.com · 5d ago
Thyroid Cancer Treatment Market to Grow with a Moderate CAGR during 2021-2029; Increasing Prevalence of Metabolic Disorders to Drive the Market Growth
May 11, 2021 (AmericaNewsHour) -- Research Nester released a report titled "Thyroid Cancer Treatment Market: Global Demand Analysis & Opportunity Outlook...
AmericaNewsHour · 6d ago
Exelixis (EXEL) Q1 Earnings Miss Estimates, Revenues Beat
Zacks.com · 05/07 17:04
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EXEL. Analyze the recent business situations of Exelixis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EXEL stock price target is 31.46 with a high estimate of 37.00 and a low estimate of 26.00.
EPS
Institutional Holdings
Institutions: 517
Institutional Holdings: 278.48M
% Owned: 88.86%
Shares Outstanding: 313.39M
TypeInstitutionsShares
Increased
83
10.51M
New
34
2.57M
Decreased
89
12.79M
Sold Out
36
2.33M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Co-Founder/Independent Director
Stelios Papadopoulos
Chief Executive Officer/President/Director
Michael Morrissey
Chief Financial Officer/Executive Vice President
Christopher Senner
Corporate Executive
Gisela Schwab
Executive Vice President/Chief Scientific Officer
Peter Lamb
Executive Vice President/General Counsel
Jeffrey Hessekiel
Executive Vice President
Patrick Haley
Independent Director
Charles Cohen
Independent Director
Carl Feldbaum
Independent Director
Maria Freire
Independent Director
Alan Garber
Independent Director
Vincent Marchesi
Independent Director
George Poste
Independent Director
Julie Smith
Independent Director
Lance Willsey
Independent Director
Jack Wyszomierski
No Data
About EXEL
Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

Webull offers kinds of Exelixis, Inc. stock information, including NASDAQ:EXEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXEL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EXEL stock methods without spending real money on the virtual paper trading platform.